Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam)
View ORCID ProfileHoward H. Feldman, José A. Luchsinger, View ORCID ProfileGabriel C. Léger, Curtis Taylor, Diane M. Jacobs, David P. Salmon, Steven D. Edland, Karen Messer, Carolyn Revta, Sarah A. Flowers, View ORCID ProfileKerry S. Jones, Albert Koulman, View ORCID ProfileKevin E. Yarasheski, Philip B. Verghese, Venky Venkatesh, Henrik Zetterberg, January Durant, View ORCID ProfileJody-Lynn Lupo, Gary E. Gibson, the ADCS BenfoTeam Study Group
doi: https://doi.org/10.1101/2024.04.19.24306070
Howard H. Feldman
1Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
2Alzheimer’s Disease Cooperative Study, University of California San Diego, La Jolla, California, United States of America
3Shiley-Marcos Alzheimer’s Disease Research Center, La Jolla, California, United States of America
José A. Luchsinger
4Columbia University Irving Medical Center, New York, New York, United States of America
Gabriel C. Léger
1Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
2Alzheimer’s Disease Cooperative Study, University of California San Diego, La Jolla, California, United States of America
Curtis Taylor
1Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
2Alzheimer’s Disease Cooperative Study, University of California San Diego, La Jolla, California, United States of America
Diane M. Jacobs
1Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
2Alzheimer’s Disease Cooperative Study, University of California San Diego, La Jolla, California, United States of America
3Shiley-Marcos Alzheimer’s Disease Research Center, La Jolla, California, United States of America
David P. Salmon
1Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
2Alzheimer’s Disease Cooperative Study, University of California San Diego, La Jolla, California, United States of America
3Shiley-Marcos Alzheimer’s Disease Research Center, La Jolla, California, United States of America
Steven D. Edland
1Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
2Alzheimer’s Disease Cooperative Study, University of California San Diego, La Jolla, California, United States of America
3Shiley-Marcos Alzheimer’s Disease Research Center, La Jolla, California, United States of America
Karen Messer
1Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
2Alzheimer’s Disease Cooperative Study, University of California San Diego, La Jolla, California, United States of America
Carolyn Revta
1Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
2Alzheimer’s Disease Cooperative Study, University of California San Diego, La Jolla, California, United States of America
Sarah A. Flowers
5University of Virginia, Charlottesville, Virginia, United States of America
Kerry S. Jones
6Nutritional Biomarker Laboratory, MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
Albert Koulman
6Nutritional Biomarker Laboratory, MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
Kevin E. Yarasheski
7C2N Diagnostics, St. Louis, Missouri, United States of America
Philip B. Verghese
7C2N Diagnostics, St. Louis, Missouri, United States of America
Venky Venkatesh
7C2N Diagnostics, St. Louis, Missouri, United States of America
Henrik Zetterberg
8Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
9Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
10Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
11UK Dementia Research Institute at UCL, London, UK
12Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China
13Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53792, USA
January Durant
1Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
2Alzheimer’s Disease Cooperative Study, University of California San Diego, La Jolla, California, United States of America
Jody-Lynn Lupo
1Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
2Alzheimer’s Disease Cooperative Study, University of California San Diego, La Jolla, California, United States of America
Gary E. Gibson
14Burke Neurological Institute, Weill Cornell Medicine, White Plains, New York, United States of America
Article usage
Posted April 19, 2024.
Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam)
Howard H. Feldman, José A. Luchsinger, Gabriel C. Léger, Curtis Taylor, Diane M. Jacobs, David P. Salmon, Steven D. Edland, Karen Messer, Carolyn Revta, Sarah A. Flowers, Kerry S. Jones, Albert Koulman, Kevin E. Yarasheski, Philip B. Verghese, Venky Venkatesh, Henrik Zetterberg, January Durant, Jody-Lynn Lupo, Gary E. Gibson, the ADCS BenfoTeam Study Group
medRxiv 2024.04.19.24306070; doi: https://doi.org/10.1101/2024.04.19.24306070
Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam)
Howard H. Feldman, José A. Luchsinger, Gabriel C. Léger, Curtis Taylor, Diane M. Jacobs, David P. Salmon, Steven D. Edland, Karen Messer, Carolyn Revta, Sarah A. Flowers, Kerry S. Jones, Albert Koulman, Kevin E. Yarasheski, Philip B. Verghese, Venky Venkatesh, Henrik Zetterberg, January Durant, Jody-Lynn Lupo, Gary E. Gibson, the ADCS BenfoTeam Study Group
medRxiv 2024.04.19.24306070; doi: https://doi.org/10.1101/2024.04.19.24306070
Subject Area
Subject Areas
- Addiction Medicine (400)
- Allergy and Immunology (711)
- Anesthesia (204)
- Cardiovascular Medicine (2961)
- Dermatology (250)
- Emergency Medicine (443)
- Epidemiology (12768)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4604)
- Geriatric Medicine (420)
- Health Economics (731)
- Health Informatics (2935)
- Health Policy (1069)
- Hematology (390)
- HIV/AIDS (927)
- Medical Education (429)
- Medical Ethics (116)
- Nephrology (472)
- Neurology (4384)
- Nursing (237)
- Nutrition (641)
- Oncology (2282)
- Ophthalmology (648)
- Orthopedics (258)
- Otolaryngology (326)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (502)
- Pediatrics (1199)
- Primary Care Research (499)
- Public and Global Health (6968)
- Radiology and Imaging (1537)
- Respiratory Medicine (917)
- Rheumatology (442)
- Sports Medicine (385)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)